<DOC>
	<DOCNO>NCT02092350</DOCNO>
	<brief_summary>This study evaluate safety efficacy combination treatment grazoprevir ( MK-5172 ) + elbasvir ( MK-8742 ) cirrhotic non-cirrhotic participant chronic Genotype 1 ( GT1 ) hepatitis C virus ( HCV ) infection chronic kidney disease ( CKD ) . The primary study hypothesis proportion HCV GT1-infected CKD participant within Immediate Treatment Intensive Pharmacokinetics ( PK ) group achieve sustained viral response 12 week end study treatment ( SVR12 ) &gt; 45 % .</brief_summary>
	<brief_title>Safety Efficacy Grazoprevir ( MK-5172 ) + Elbasvir ( MK-8742 ) Participants With Chronic Hepatitis C Chronic Kidney Disease ( MK-5172-052 )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<criteria>Documented chronic ( least 6 month ) HCV GT 1 infection ( evidence mix genotype genotype assign type ) Evidence evidence liver cirrhosis base one following : Liver biopsy perform within 24 month Day 1 ( participant cirrhotic time restriction biopsy ) Fibroscan perform within 12 month Day 1 study Fibrosure™ ( Fibrotest™ ) plus aspartate aminotransferase platelet Ratio Index [ APRI ] obtain screen period ) Has HCV status one following : Treatment naïve Prior interferon pegylated interferon without ribavarin failure ( null responder , partial responder , relapser ) Intolerant prior interferon pegylated intereferon without ribavarin regimen Chronic kidney disease ( defined glomerular filtration rate [ eGFR ] &lt; =29 ) nondialysis dependent hemodialysis least 3 month , include individual await kidney transplant fail kidney transplant longer immunosuppressant therapy ) Female participant reproductive potential must agree remain abstinent use ( partner use ) 2 acceptable method contraception least 2 week prior Day 1 14 day last dose study drug , longer dictate local regulation Evidence decompensated liver disease On peritoneal dialysis management kidney disease Coinfection hepatitis B virus human immunodeficiency virus ( HIV ) History malignancy &lt; =5 year prior sign inform consent Clinical diagnosis substance abuse Pregnant , breastfeeding , expect conceive donate egg , donate sperm Day 1 14 day last study dose , longer dictate local regulation Organ transplant ( include hematopoietic stem cell transplant ) kidney , cornea , hair Conditions requiring , likely require , chronic systemic administration corticosteroid course trial Uncontrolled poorly control hypertension Significant cardiovascular disorder ( e.g . myocardial infarction unstable angina ) cardiovascular procedure within 3 month prior sign inform consent New worsen sign symptom congestive heart failure within 3 month sign informed consent Severe active peripheral vascular disease Recent ( within 3 month prior sign informed consent ) episode recurrence stroke , transient ischemic attack ( TIA ) neurological disorder , include limited seizure Evidence history chronic hepatitis cause HCV</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>